Alliance Healthcare UK has appointed Paula Sutherland as sales director to lead its sales teams in delivering products and services to community pharmacies.
In her new role, Paula will focus on ensuring that the company's offerings align with the unique needs of pharmacies and their patients.
Since joining Alliance Healthcare in 2012, Paula has held various leadership roles that have focused on building strong relationships with community pharmacies,
manufacturer partners, and hospital services.
Her extensive experience is expected to further strengthen the company's partnerships with community pharmacies.
Before joining Alliance Healthcare, Paula gained valuable experience in commercial roles within the fast-moving consumer goods sector, at companies such as
Perrigo UK and global supply-chain logistics company CHEP.
The Royal Pharmaceutical Society (RPS) has appointed Neville Carter as its new chief education and membership officer.
Neville joins RPS from the Royal Society of Medicine (RSM) where he is currently director of engagement, leading a team of over 60 and responsible for creating a
combined directorate accountable for education, membership, philanthropy, and business development.
He has, in particular, led on the development of a digital education strategy and launched professional development training programmes for members.
Prior to joining the RSM, Neville worked as director of product and sales at the British Medical Association with responsibility for membership growth, supporting
corporate transformation and developing and managing member benefits and relationships with third-party providers to support revenue growth. He also has senior
manager experience at the RAC and at British Airways.
Commenting on the appointment, Paul Bennett, RPS CEO, said: "I'm delighted that Neville will be joining our Executive team. He brings a wealth of relevant experience
and this, in combination with a strong existing education and membership team at RPS and a clear ambition to strengthen the relevant functions further, will enable
the organisation to deliver a dynamic offering for our members.
Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches - a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a pharmacist.
Ian brings over 30 years' international consumer health and personal care experience to the Maxwellia team. He is currently an advisor to the board of the UK
independent pharmacy chain Day Lewis plc, an advisor to the board of Spanish healthcare company ReVa Europe S.L and board advisor to East Midlands Pharmaceuticals
Ltd.
Prior to this Ian was Chief Commercial Officer and a main board director at SSL International plc (prior to its sale to Reckitt Benckiser) with responsibility for a $1bn portfolio of brands, which included Durex and Scholl.
Ian's appointment follows the landmark reclassification of the progestogen only pill by the MHRA, a change spearheaded by Maxwellia, and the company's subsequent
launch of its first product Lovima in July 2021; and the current MHRA public consultation on the reclassification of Maxwellia's new pharmacy brand, Aquiette 2.5mg Tablets (Oxybutynin Hydrochloride) for the treatment of overactive bladder symptoms which are not adequately controlled by bladder training alone.
AAH Pharmaceuticals (AAH) has announced the appointment of Brain Chambers as Chief Commercial Officer.
"I'm proud to lead the commercial functions in AAH in my new role and broader area of responsibility." Said Brian. "I'm committed to delivering on great value for
our customers and building and strengthening our supplier partnerships."
Brain is associated with AAH Pharmaceuticals for more than 14 years. He joined the organisation as Business Development Manager in October 2008. His previous role
in the organisation was on Sales and Marketing Director.
He posted on LinkedIn: "This is a big move for me personally, but that's a side hustle. What is the main play here is AAH becoming a standalone independent wholesale
business focussed on only the AAH customer and our core business and this is just one part of that.
Pharmacy hub and spoke specialists, Centred Solutions, has further strengthened its team with a key new appointment as the company expands its business.
Ashley Kilgas, formerly sales director at Alliance Healthcare, has joined the company's executive team as chief commercial officer.
An expert in sales leadership and customer relations with vast experience working in the healthcare and pharmacy sector, Kilgas will be tasked with building
a high-performing commercial team to drive value for customers.
Having worked closely with Centred Solutions on previous projects, Ashley already has an in-depth knowledge of the business.
Expressing his excitement about his new role, Ashley said: "Centred Solutions is a pharmacy technology and automation company, with a tremendous amount of
opportunity in front of it. There is currently nobody in the market with the same knowledge, expertise or product offering around hub and spoke.
"While the company is still in its infancy, it is growing rapidly, and I am looking forward to working with the team to further strengthen and grow the
business to support those working in pharmacy."
Boehringer Ingelheim UK & Ireland has appointed Vani Manja as its new Country Managing Director and Head of Human Pharma.
Manja has been associated with Boehringer Ingelheim for over 11 years, in successful leadership roles in Germany, the United States and most recently as General
Manager, India.
Her career started as a commissioned officer in the Indian Army Ordnance Corps which preceded leadership roles at Becton Dickinson and McKinsey.
She brings extensive experience of strategy, marketing, sales, business development, people management, and cultural transformation and is passionate about tackling
healthcare inequalities and advancing sustainable healthcare.
Commenting on her new role, Manja said: "It is with great heart that I bring the spirit of conscious leadership to my new role. I look forward to being fully present
and partnering with key stakeholders in the healthcare ecosystem in our collective quest to improve health for humans and animals in the UK and Ireland."
Perrigo, one of the world's largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation
DACH Cluster.
van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and
Granu Fink.
He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter
& Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as
multifunctional Team Leader Emerging Channels.
The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General
Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several
business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance Business Partner
Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.